FOCUS On Kinase Inhibitors. The FDA recently approved its 100th kinase inhibitor, marking a major milestone in precision medicine since its first kinase inhibitor approval (Imatinib) in 2001. Novartis recently received approval for Remibrutinib (Rhapsido), the only oral targeted BTK inhibitor treatment for chronic spontaneous urticaria (CSU). Remibrutinib inhibits the release of histamine and other proinflammatory mediators by targeting BTK, offering a unique approach to CSU treatment.
Focus Biomolecules can supply Remibrutinib for research applications. Contact us for more information.
